Select Page

The global irritable bowel syndrome treatment market is expected to exhibit a strong 7.58% CAGR over the forecast period from 2018 to 2023, according to the latest research report from Market Research Future (MRFR).   

According to Market Research Future (MRFR)’s new study, the global irritable bowel syndrome treatment market is projected to thrive at a CAGR of 7.58% during the forecast period 2018 to 2023. The valuation of the global market has been estimated to reach USD 2,988.6 Mn towards the end of 2023 from USD 1,890.9 Mn in 2017. It is presumed to scale new heights over the next few years owing to the consolidation of a substantial patient population. 

The constantly increasing economic burden of IBS affects work productivity and leads to an increase in healthcare costs. This, in turn, has raised awareness about the disorder, thus, favoring the expansion of the global market. In addition, the large-scale prevalence of anxiety and depression is anticipated to catalyze the growth of the irritable bowel syndrome treatment market over the assessment period. 

The key players are continually investing in drug development for capitalizing on the rising patient pool. Furthermore, the collaborations among the key players are supposed to have a positive influence on the proliferation of the irritable bowel syndrome treatment market. On the flip side, stringent regulations framed by governments and limited patient satisfaction are predicted to hinder the proliferation of the market during the assessment period. 

 

Irritable Bowel Syndrome Treatment Market Competitive Analysis:  

Leading players in the global irritable bowel syndrome treatment market include Abbott, Mallinckrodt, Ardelyx Inc., Ironwood Pharmaceuticals, Synergy Pharmaceuticals Inc., Nestle Health Science, Lexicon Pharmaceuticals Inc., Astellas Pharma Inc., Allergan Inc., and Valeant.   

In August 2019, IBS-related startup metaMe Health raised USD 3.8 million in a funding round led by LionBird Ventures.   

Avail Free Sample @ https://www.marketresearchfuture.com/sample_request/7044 
 

Irritable Bowel Syndrome Treatment Market Segmentation:  

The global irritable bowel syndrome treatment market is segmented on the basis of type, drug type, end user, and region.   

By type, the global irritable bowel syndrome treatment market is segmented into IBS-D, IBS-C, and IBS-M. IBS-D is likely to remain the majority shareholder in the global irritable bowel syndrome treatment market over the forecast period.   

By drug type, the global irritable bowel syndrome treatment market is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, and alosetron. Linaclotide is likely to remain the major segment in the global irritable bowel syndrome treatment market by drug type.  

By end use, the global irritable bowel syndrome treatment market is segmented into hospitals, clinics, research laboratories, and others. Hospitals hold the dominant share in the global irritable bowel syndrome treatment market and are likely to remain the leading segment over the forecast period.   

Irritable Bowel Syndrome Treatment Market Regional Analysis:  

North America is likely to dominate the global irritable bowel syndrome treatment market over the forecast period due to the growing prevalence of the disease and the growing awareness about the disease in the region. The growing prevalence of IBS in North America is majorly driven by the increasing prevalence of a dietary pattern dependent on junk food to make up the calorific load, as this results in irritable bowel syndrome. Growing demand for junk food in urban centers in North America is likely to be a major driver for the irritable bowel syndrome treatment market over the forecast period. Junk food, which contains lots of calories but usually little fiber, is a major causative agent for irritable bowel syndrome, and is thus likely to remain in the eye of the storm with regard to the prevalence of irritable bowel syndrome in the coming years. The increased prevalence of smoking among adults in North America is also likely to be a major driver for the irritable bowel syndrome treatment market over the forecast period.   

Increasing awareness about the disease in North America is likely to remain a key driver for the global irritable bowel syndrome treatment market over the forecast period. The increasing prevalence of the disease and the presence of strong population health management protocols in the U.S. is likely to be a major driver for the growing irritable bowel syndrome treatment market over the forecast period. Hospitals and other healthcare agencies in the region are now wise to the threat of irritable bowel syndrome and know exactly how to tackle it. This is likely to remain a major driver for the irritable bowel syndrome treatment market over the forecast period.   

Europe is also likely to remain a major regional market for the global irritable bowel syndrome treatment market over the forecast period. Widespread presence of strong healthcare agencies in the region, particularly in the highly developed Central and Western Europe regions, is likely to remain a major driver for the irritable bowel syndrome treatment market in the region over the forecast period. The high awareness about irritable bowel syndrome in Europe is likely to remain a vital driver for the global irritable bowel syndrome treatment market over the forecast period. The increasing popularity of smoking in Europe is likely to be a major driver for the irritable bowel syndrome treatment market over the forecast period.   

Asia Pacific is likely to exhibit steady growth in the global irritable bowel syndrome treatment market over the forecast period, due to the growing demand for irritable bowel syndrome treatments from the vast population in the region. The growing scope of the market in the vast regional market of Asia Pacific, which is also the most populous region in the world, is likely to remain a major driver for the irritable bowel syndrome treatment market over the forecast period.   

Browse Complete Report with TOC @ https://www.marketresearchfuture.com/reports/irritable-bowel-syndrome-treatment-market-7044